A 40-Year-Old Law Continues to Produce New Jobs Today


By Robin Rasor

This fall, tens of millions of Americans will get vaccinated against influenza -- but they won't all experience a prick in the arm. Instead, many will take FluMist, the painless nasal flu vaccine.

FluMist is just one of many breakthrough innovations that originated at the University of Michigan, where I served as Managing Director of Licensing within the Office of Tech Transfer for over a decade. I now serve as Executive Director of Duke University's Office of Licensing & Ventures which has a similar portfolio of innovations including Krystexxa, a treatment for refractory gout.

Over my many years at three universities, I've seen countless, life-changing discoveries come out of university research labs, the majority of them resulting from federal funding. But these research discoveries would have never made it off of college campuses if it weren't for bipartisan legislation passed 40 years ago -- the Bayh-Dole Act.

The Bayh-Dole Act enables universities, non-profits, and other publicly-funded institutions to patent their discoveries -- and license those patents to private companies. Before it became law, the government retained the patents on all taxpayer-funded research. Much of it never saw the light of day.

Bayh-Dole is based on a simple insight: Universities excel at basic research, but they lack the resources and expertise to turn those discoveries into functioning products. Private companies, on the other hand, are willing to take big risks -- but they're not well suited to perform extremely early-stage research.

The law's architects, Senators Birch Bayh (D-IN) and Bob Dole (R-KS), realized that it's far more efficient for universities to partner with the private sector to further develop and commercialize new inventions.

By harnessing the creativity of research institutions alongside the capital and innovative know-how of the private sector, Bayh-Dole has fueled decades of job-creation and entrepreneurship. Since 1996, the practice of licensing academic inventions to the private sector has supported up to 5.9 million jobs and generated up to $1.7 trillion in economic output. Bayh-Dole is also responsible for some 13,000 start-ups, by one estimate.

The law has also been a boon for American workers. It has created new positions at startups and existing companies that license university technologies. Economists are quick to point out these opportunities, but sometimes overlook an entirely new profession spurred by Bayh-Dole: my own, that of technology transfer specialist.

I've worked in the tech transfer field for over three decades, helping university researchers license their discoveries to the private sector. However, when I was in college and graduate school, the tech transfer profession didn't even exist.

Now universities employ thousands of professionals like me and the tech transfer profession, and related careers, is poised to grow in the years ahead. In fact, many top universities, including Duke, offer technology-transfer fellowships for graduate students to provide them with on-the-job experience in this burgeoning field.

The Bayh-Dole Act also fosters a vibrant biopharmaceutical sector that directly employs over 800,000 Americans while supporting more than 4 million jobs indirectly. Direct biopharmaceutical industry jobs, on average, pay twice as much as other private sector jobs.

At a time when our country needs economic dynamism more than ever, we should do everything in our power to encourage risk-taking and innovation. Thankfully, the Bayh-Dole Act exists to help us do just that. And, I for one, am thankful for a wonderfully fulfilling career that I might not have had otherwise.

Robin Rasor is executive director of the Duke University Licensing & Ventures Office.

More Resources


03/29/2024
2024, an Election About Elections
The new poll out from Fox News has a number of intriguing findings.

more info


03/29/2024
The Overlooked Truths About Biden's Age
In terms of optics and in terms of energy, I wish President Biden were younger. There's no point in pretending

more info


03/29/2024
Biden, Obama & Clinton Join Forces in NY
Thursday on the RealClearPolitics radio show (Monday through Friday at 6:00 p.m. EDT on SiriusXM's P.O.T.U.S. Channel 124), Carl Cannon, Tom Bevan and Emily Jashinsky discuss: Joe Lieberman's passing, Bobby Kennedy Jr.'s appeal to voters, the environment of victimization culture, Sam Bankman-Fried's 25-year prison sentence, and James Carville's riff on "preachy" Democrats.

more info


03/29/2024
Meddlers for RFK Jr.
Democrats may get bitten by a tactic they use to great effect in GOP primaries.

more info


03/29/2024
Will RFK Jr.'s Support for Israel Limit His Appeal on Left?
Robert F. Kennedy Jr.'s independent presidential campaign goes to considerable lengths to profess its potential appeal to people across the partisan and ideological landscape.

more info


03/29/2024
Joe Lieberman's Last Words on Israel
A warning to Biden that he risks losing the votes of Jewish Democrats like us.

more info


03/29/2024
A Senator Who Loved To Kibitz


more info


03/29/2024
Behind Scenes Stories of Censorship
Dave Rubin of "The Rubin Report" hosts a panel with the winners of the first RealClearPolitics Samizdat Prize -- "Twitter Files" journalist Matt Taibbi, "Great Barrington Declaration" co-author Dr. Jay Bhattacharya, and NY Post reporter and "Laptop From Hell" author Miranda Devine. The three were chosen for their bravery in resisting censorship. They discuss the cost of taking a stand as well as the future of free speech and online discourse.

more info


03/29/2024
Bidenomics Is Making China Angry. That's OK
A persistent theme in Republican campaigning these past few years has been the effort to portray Democrats in general, and

more info


03/29/2024
Biden's Boss Tightens the Screws


more info


03/29/2024
The Fight To Flip the House Just Got Harder for Dems


more info


03/29/2024
In 2024, Digital Is Everything in Politics


more info


03/29/2024
Comer Sums Up His 'Evidence' of Biden Crimes. It's Scant


more info


03/29/2024
WaPo's Lead Liar Waves Away Evidence of Biden Corruption
Glenn Kessler pretended to 'dissect' Rep. James Comer's comments but did not challenge any of the evidence the Republican mentioned.

more info


03/29/2024
Sam Bankman-Fried's Dream Came True


more info



Custom Search

More Politics Articles:

Related Articles

Every American Has Troubles


Everybody has troubles. If you don't believe it then ask any American living in the year 2020.

We Need New Antimicrobials To Prevent the Next Infectious Disease Crisis


Imagine if scientists had seen Covid-19 coming years in advance yet did little to prepare. Unthinkable, right?

I Like Ike


As other statues and monuments are being removed or criticized throughout our nation, a new $150 million memorial located near the U.S. Capitol will be dedicated Thursday honoring the general who helped defeat the Axis Powers in World War II and the president who worked diligently to preserve peace during the Cold War.

A Coronavirus Vaccine Doesn't Mean the Pandemic is Over


Dr. Anthony Fauci thinks that drug companies may develop a COVID-19 vaccine before year's end.

President Trump's Latest Executive Order Will Decimate U.S. Innovation


With only a few months left in his first term, President Trump is trying to make good on his campaign promise to lower drug prices.

A 40-Year-Old Law Continues to Produce New Jobs Today


This fall, tens of millions of Americans will get vaccinated against influenza -- but they won't all experience a prick in the arm. Instead, many will take FluMist, the painless nasal flu vaccine.

Will the Doctor See Me Now?


Imagine you're traveling out of state to visit family. When you're 15 minutes from grandma's house, you decide to let her know you'll be arriving soon.

Republican or Democrat, Foreign Reference Pricing Kills Cures


The pharmaceutical industry is on a bit of a hot streak. Just last month, both Pfizer and Moderna received FDA approval for their COVID-19 vaccines. Millions of Americans have already received them.

"March In" Is Not the Answer


All Democrats and many Republicans are committed to making prescription drugs more affordable.

Is President Biden the "Sinner-In-Chief" for Promoting Easier Access to Abortions?


Archbishop Joseph Naumann, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, has taken President Biden to task for touting his faith while at the same time promoting abortions.

A Bad Means to a Bad End


What happens in a world where medical innovations like the vaccines that are defeating the coronavirus are no longer possible? That could be the result of a ham-handed effort to make America an "also-ran" country in the global pharmaceutical business.

Price Controls Happen — NOT!


The end of the pandemic is in sight, thanks in large part to the heroic efforts of the biopharmaceutical industry. American companies developed not one, but three vaccines in under a year, and roughly 3 million people are receiving those shots every day.

Foreign Drug Pricing Puts America's Most Vulnerable Patients Last


It's no coincidence that American companies led the charge to develop Covid-19 vaccines. Numerous policies -- from strong patent protections to a welcoming immigration system -- help ensure that the world's smartest scientists can pursue cutting-edge research here.

In the Fight Against Climate Change, Don't Overlook Biotech


President Biden has already laid out an ambitious climate change agenda. With a series of early executive orders, he set the stage for a ban on oil and gas drilling on federal land, an end to fossil fuel subsidies, and a transition to electric engines in government vehicles.

Don't Sabotage the Engine of American Ingenuity


It's no surprise that most of the companies behind the most effective Covid-19 vaccines are American.